448 related articles for article (PubMed ID: 15111503)
41. GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion.
Cani PD; Holst JJ; Drucker DJ; Delzenne NM; Thorens B; Burcelin R; Knauf C
Mol Cell Endocrinol; 2007 Sep; 276(1-2):18-23. PubMed ID: 17681422
[TBL] [Abstract][Full Text] [Related]
42. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
43. [GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
Thorens B
Journ Annu Diabetol Hotel Dieu; 2004; ():111-25. PubMed ID: 15259310
[No Abstract] [Full Text] [Related]
44. Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype.
Flamez D; Gilon P; Moens K; Van Breusegem A; Delmeire D; Scrocchi LA; Henquin JC; Drucker DJ; Schuit F
Diabetes; 1999 Oct; 48(10):1979-86. PubMed ID: 10512362
[TBL] [Abstract][Full Text] [Related]
45. Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner.
Esser N; Barrow BM; Choung E; Shen NJ; Zraika S
Islets; 2018; 10(5):175-180. PubMed ID: 30142012
[TBL] [Abstract][Full Text] [Related]
46. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.
Ahrén B; Holst JJ; Mårtensson H; Balkan B
Eur J Pharmacol; 2000 Sep; 404(1-2):239-45. PubMed ID: 10980284
[TBL] [Abstract][Full Text] [Related]
47. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Winkler G
Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
[TBL] [Abstract][Full Text] [Related]
48. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
[TBL] [Abstract][Full Text] [Related]
49. The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors.
Ahrén B; Yamada Y; Seino Y
J Endocr Soc; 2020 Feb; 4(2):bvz036. PubMed ID: 32010875
[TBL] [Abstract][Full Text] [Related]
50. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
51. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice.
Baggio L; Kieffer TJ; Drucker DJ
Endocrinology; 2000 Oct; 141(10):3703-9. PubMed ID: 11014225
[TBL] [Abstract][Full Text] [Related]
52. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
[TBL] [Abstract][Full Text] [Related]
53. Cardiovascular biology of the incretin system.
Ussher JR; Drucker DJ
Endocr Rev; 2012 Apr; 33(2):187-215. PubMed ID: 22323472
[TBL] [Abstract][Full Text] [Related]
54. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
55. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.
Deacon CF; Hughes TE; Holst JJ
Diabetes; 1998 May; 47(5):764-9. PubMed ID: 9588448
[TBL] [Abstract][Full Text] [Related]
56. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
57. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
58. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors.
Preitner F; Ibberson M; Franklin I; Binnert C; Pende M; Gjinovci A; Hansotia T; Drucker DJ; Wollheim C; Burcelin R; Thorens B
J Clin Invest; 2004 Feb; 113(4):635-45. PubMed ID: 14966573
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
60. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
